Artificial intelligence is fundamentally reshaping our approach to clinical trials by accelerating protocol development, reducing costly amendments, and improving the predictability of study outcomes. This article demonstrates how AI and in silico methods strategically augment human expertise throughout every stage of trial design, especially in high-complexity areas such as oncology, CNS, and rare diseases. We provide a clear framework that shows where AI has the greatest impact and highlight how leading organizations are actively deploying these capabilities today.
Read the full article to explore:
- How AI is changing protocol drafting, consistency checking, and regulatory compliance
- The role of digital twin models and in silico patient simulations in guiding trial planning and predicting study outcomes before a single patient is enrolled
- A practical breakdown of where AI capabilities excel and where the irreplaceable “human-in-the-loop” remains essential to sound trial design
- The leading AI tools and their applications across protocol development and patient recruitment
